This is a preview of subscription content, log in via an institution to check access.
Notes
2009 Australian dollars
Reference
Adena M, et al. Modelling the Cost Effectiveness of Rituximab in Chronic Lymphocytic Leukaemia in First-Line Therapy and Following Relapse. PharmacoEconomics : 18 Jan 2014
Rights and permissions
About this article
Cite this article
Rituximab cost effective for CLL in Australia. PharmacoEcon Outcomes News 695, 8 (2014). https://doi.org/10.1007/s40274-014-1011-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-014-1011-z